Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1626
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18599902 | Treatments for Diabetes Mellitus and Obesity | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19239326 | NASAL COMPOSITION | Final Rejection | SATO PHARMACEUTICAL CO., LTD. |
| 18638204 | NASAL COMPOSITION | Final Rejection | SATO PHARMACEUTICAL CO., LTD. |
| 18245941 | PHARMACEUTICAL COMPOSITION CONTAINING AS ACTIVE INGREDIENT COMPOUND CONJUGATED TO G4 STRUCTURES OF CORONAVIRUSES FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTIOUS DISEASES | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18530612 | METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY | Non-Final OA | Massachusetts Institute of Technology |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | Non-Final OA | Bristol-Myers Squibb Company |
| 18126547 | COMPOSITIONS FOR INHIBITING 3' REPAIR EXONUCLEASE 2 AND METHODS OF SCREENING FOR SUCH COMPOSITIONS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18109406 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | Final Rejection | CASE WESTERN RESERVE UNIVERSITY |
| 17588104 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18167110 | AMINO ACID COMPOSITIONS AND USES THEREOF | Final Rejection | AMILYFE, LLC |
| 18480145 | COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING POLY-y-GLUTAMIC ACID ISOLATED FROM BACILLUS AS ACTIVE INGREDIENT | Non-Final OA | PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION |
| 18663524 | Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization | Non-Final OA | BAYLOR COLLEGE OF MEDICINE |
| 18213177 | COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDS AND ANTIEMETIC AGENTS | Non-Final OA | NURIX THERAPEUTICS, INC. |
| 18033345 | METABOLIC ACTIVATORS FOR ENHANCING SPERM CAPACITATION IN MAMMALS | Non-Final OA | UNIVERSIDADE DO PORTO |
| 18245293 | APPLICATION OF ESTER GROUP-CONTAINING AROMATIC PROPIONAMIDE COMPOUNDS IN PREPARATION OF DRUGS FOR TREATING URINARY INCONTINENCE | Non-Final OA | CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. |
| 18239740 | NATURAL DIETARY SUPPLEMENT FOR MENTAL HEALTH | Non-Final OA | Mind Pop LLC |
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | Non-Final OA | Ann And Robert H. Lurie Children's Hospital of Chicago |
| 18144230 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY COMPRISING MELATONIN AND PROSTAGLANDIN E2 FOR TREATING INTESTINAL EPITHELIAL INJURY AS AN ACTIVE INGREDIENT | Non-Final OA | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION |
| 18157438 | METHODS AND SYNERGIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | Final Rejection | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. |
| 17741719 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN CORONAVIRUS DISEASE (COVID-19) | Final Rejection | PHARMAZZ, INC. |
| 18256750 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | Non-Final OA | Sanquin IP B.V. |
| 18032320 | USE OF BENZODIAZEPINES TO INCREASE SENSITIVITY TO PSILOCYBIN FOLLOWING A CHRONIC SSRI REGIMEN | Non-Final OA | Compass Pathfinder Limited |
| 18252843 | SUBSTANCES FOR TREATMENT OF HYPERURICAEMIA | Non-Final OA | SCANDIBIO THERAPEUTICS AB |
| 18188413 | COMPOSITON AND METHOD FOR PREVENTION AND TREATMENT OF CUTANEOUS RADIATION INJURY | Non-Final OA | Rythera Therapeutics, Inc. |
| 16954105 | COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY | Non-Final OA | Actinium Pharmaceuticals, Inc. |
| 18044964 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Final Rejection | Accencio LLC |
| 18024831 | COMPOSITION COMPRISING CANNABINOIDS, AND/OR TERPENS, AND METHODS OF USING SAME | Final Rejection | MEDICANE RESEARCH & DEVELOPMENT LTD |
| 18107835 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC KIDNEY DISEASE | Non-Final OA | Chengdu WenDing Technology Development Co., Ltd. |
| 17906962 | ANTI-INFLAMMATORY IMMUNOENHANCER | Non-Final OA | SCENT SCIENCE INTERNATIONAL INC. |
| 18017317 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | Non-Final OA | ZEPHAPHARM LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy